$CYTK News

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics Announces First Commercial European Launch Of MYQORZO In Germany For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients

Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech Stocks

Cytokinetics to Participate in June Investor Conferences

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics to Hold Annual Meeting of Stockholders

Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $99

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11%

JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Presents New Data From Its SEQUOIA-HCM Pivotal Phase 3 Clinical Study Of Aficamten In Participants With oHCM; MAPLE-HCM At European Society Of Cardiology Heart Failure 2026 Congress

Identifix’s Direct-Hit® Mobile Brings OEM Repair Manuals to the Bay, Transforms How Repairs Get Done

HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $140

Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (Rating Downgrade)

Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says